Murray, Esq.Dewey & LeBoeuf LLP1301 Avenue of the AmericasNew York, New York 10019(212) 259-8000Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective date of this Registration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
the offer or sale is not permitted.Subject to Completion, dated July 31, 2008Preliminary Prospectus SupplementTo Preliminary Prospectus dated July 31, 20085,000,000 SharesCommon StockThe selling stockholders named in this prospectus supplement are offering for resale 5,000,000 shares of our common stock, par value
prospectus.Per shareTotalPublic offering price$$Underwriting discounts and commissions$$Proceeds to selling stockholders, before expenses$$The selling stockholders have granted the underwriters an option for a period of 30 days to purchase up to 750,000 additional shares of common stock on the same terms and conditions set
convertible preferred stock, which was issued to finance the March 2007 PDSHeart acquisition, was converted to common stock in connection with our March 2008 initial public offering.The information included above for the three and six months ended June 30, 2007 and 2008 for operating income, net income and earnings per share includes information that has not
On a consolidated basis, for the three months ended March 31, 2008, our revenues were $25.5 million.S-3The OfferingCommon stock offered by the selling stockholders5,000,000 sharesOver-allotment optionThe selling stockholders have granted the underwriters an option for a period of 30 days to purchase up to 750,000 additional shares of common stock.Common stock to be outstanding after this offering22,985,279 sharesUse of proceeds.We will not receive any of the proceeds from the sale of common stock by the selling stockholders.
If all of the shares are not sold at the initial offering price, the representatives may change the public offering price and the other selling terms.The selling stockholders have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to
common stock, pursuant to, and the filing of a registration statement relating to, any employee stock option plan, stock ownership plan or dividend reinvestment plan of the Company currently in effect
(within the meaning of section 21 of the Financial Services and Markets Act 2000 ("FSMA")) received by it in connection with the issue or sale of any shares included in this offering in
prospectus carefully, including the "Risk Factors" section and the consolidated financial statements and related notes included in this prospectus.The CompanyOverviewWe are the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical
common stock in connection with our March 2008 initial public offering.The information included above for the three and six months ended June 30, 2007 and 2008 for operating income, net income and earnings per share includes information that has not
event monitoring services to approximately 76,000 patients, representing approximately 80% of PDSHeart's $20.9 million in revenues for the year ending December 31, 2006.
event monitoring services to approximately 76,000 patients, representing approximately 80% of PDSHeart's $20.9 million in revenues for the year ending December 31, 2006.
impacting clinical outcomes and health care costs.CardioNet SolutionWe have developed an ambulatory, continuous and real-time arrhythmia monitoring solution that we believe represents a significant advancement over
Physicians can review the data by fax or internet, depending on their preferences.Our Business StrategyOur goal is to maintain our position as the leading provider of ambulatory, continuous and real-time outpatient monitoring services by establishing
below are not necessarily indicative of results for future periods.8ActualPro FormaActualThree months ended March 31,Year ended December 31,(in thousands, except share and per share data)200520062007200720072008(unaudited)(unaudited)Statement of Operations Data:Revenues:Patient revenues$29,467$33,019$72,357$76,412$10,957$25,248Other revenues1,471904635649143215Total revenues30,93833,92372,99277,06111,10025,463Cost of revenues16,96312,70125,52627,1723,7909,519Gross profit13,97521,22247,46649,8897,31015,944Operating expenses:Research and development3,3613,6313,7823,7829901,141General and administrative13,85315,63127,47428,7005,2019,066Sales and marketing6,4566,44815,96817,0303,3205,115Integration, restructuring and other nonrecurring charges—————1,306Total expenses23,67025,71047,22449,5129,51116,628Income (loss) from operations(9,695)(4,488)242377(2,201)(684)Other income (expense):Interest income971141,6221,627223178Interest expense(1,865)(3,271)(2,222)(2,264)(1,176)(66)Total other income (expense)(1,768)(3,157)(600)(637)(953)112Loss before benefit from income taxes(11,463)(7,645)(358)(260)(3,154)(572)Income tax expense (benefit)—————232Net income (loss)$(11,463)$(7,645)$(358)$(260)$(3,154)$(340)Dividends on and accretion of mandatorily convertible preferred stock——(8,346)(8,346)(482)(2,597)Net loss applicable to common shares$(11,463)$(7,645)$(8,704)$(8,606)$(3,636)$(2,937)Basic and diluted net loss per share(1):Historical$(4.04)$(2.63)$(2.89)$(2.86)$(1.22)$(0.63)Pro Forma$(0.51)Shares used to compile basic and diluted net loss per share(1)Historical2,837,7722,908,3603,011,6993,011,6992,993,0614,694,561Pro Forma16,839,493(1)Please
shares used in computation of the per share amounts.As of March 31, 2008(in thousands)Consolidated Summary Balance Sheet Data (unaudited):Cash and cash equivalents$61,973Working capital71,958Total assets154,766Total debt2,872Total shareholders' equity135,3519In accordance with regulations of the Securities and Exchange Commission, the tables set forth below reconcile certain
operate our call center in Florida or to comply with any other state requirements to which we are subject, our business and results of operations could be adversely impacted.We may be subject to federal and state false claims laws which impose substantial penalties.Many of the physicians and patients who use our services file claims for reimbursement with government programs such as Medicare and Medicaid.
measures to control costs, or reductions in reimbursement levels, which may adversely affect our business and results of operations.23Changes in the health care industry or tort reform could reduce the number of arrhythmia monitoring solutions ordered by physicians, which could result
upon the exercise of a warrant to purchase up to 6,250 shares of our common stock) have rights, subject to some conditions, to require us to file registration statements covering their shares or to
influencing significant corporate decisions and may harm the market price of our common stock.Including stock options that are exercisable within 60 days of March 31, 2008, our existing principal stockholders, executive officers and
of this prospectus or any applicable prospectus supplement that include forward-looking statements.28USE OF PROCEEDSWe will not receive any proceeds from the sale of shares of our common stock by the selling stockholders in this offering.PRICE RANGE OF COMMON STOCKOur common stock has been traded on the Nasdaq Global Market under the symbol "BEAT" since March 19, 2008.
and Results of Operations" appearing elsewhere in this prospectus.As of March 31, 2008Actual(unaudited)(in thousands, exceptshareand per share data)Debt obligations:Note payable to shareholder (net of discount)$—Long term debt, including current portion2,872Common stock: 200,000,000 shares authorized, 22,985,279 shares issued and outstanding; $0.001 par value23Preferred stock: 10,000,000 shares authorized, 0 shares issued and outstanding; $0.001 par value0Additional paid-in capital217,388Deferred compensation—Accumulated deficit(82,060)Total shareholders' equity (deficit)135,351Total capitalization$138,223The
shares of common stock issuable upon the exercise of an outstanding warrant having an exercise price of $2.94 per share.30UNAUDITED PRO FORMA CONSOLIDATED STATEMENTS OF OPERATIONSThe following unaudited pro forma consolidated statements of operations for the year ended December 31, 2007 are based on the historical statements of
statements of operations.31CardioNet, Inc.Unaudited Pro Forma Consolidated Statement of OperationsYear ended December 31, 2007(in thousands, except share and per share data)Twelve MonthsConsolidatedCardioNetJanuary 1toMarch 7PDSHeartNotesPro FormaAdjustmentsPro FormaConsolidated(unaudited)Revenues:Net patient revenues$72,357$4,055$—$76,412Other revenues63514—649Total revenues72,9924,069—77,061Cost of revenues25,526(1,646)—27,172Gross profit47,4662,42349,889Operating expenses:Research and development3,782——3,782General and administrative26,6751,128(a)(88)27,715Sales and marketing15,9681,098(b)(36)17,030Amortization79932(c)154985Total expenses47,2242,2583049,512Income (loss) from operations242165(30)377Other income (expense):Interest income1,6225—1,627Interest expense(2,222)(122)(d)80(2,264)Total other income (expense)(600)(117)80(637)Income tax (expense) benefit————Net income (loss)(358)4850(260)Dividends on and accretion of mandatorily redeemable convertible preferred stock(8,346)——(8,346)Net loss available to common shareholders$(8,704)$48$50$(8,606)Basic and diluted net loss available to common shareholders per share$(2.89)$(2.86)Shares used to compute basic and diluted net loss available to common shareholders per share3,011,6993,011,69932CardioNet, Inc.Notes to Unaudited Pro Forma Consolidated Statements of OperationsBasis of Pro Forma PresentationsOn March 8, 2007, we acquired PDSHeart, Inc. for an aggregate purchase price of $51.6 million.
The following is a summary of our purchase price allocation (in thousands):Aggregate purchase price consideration$55,180Acquisition related costs1,415Total purchase price$56,595Net tangible assets$7,334Other accruals(344)Identifiable intangible assetsTrade Name1,810Customer Relationships1,551Non Compete Agreements245Goodwill45,999Total allocated purchase price$56,59533Pro Forma AdjustmentsThe following table summarizes the pro forma adjustments for the respective periods presented (in thousands):Year EndedDecember 31, 2007(a)Elimination of executive salary$88(b)Elimination of marketing salary36(c)Additional amortization expense(154)(d)Reduction of interest expense80Net reduction in net loss$50(a)Reflects
The interim results set forth below are not necessarily indicative of results for future periods.Year ended December 31,Three months endedMarch 31,2003200420052006200720072008(unaudited)(unaudited)(in thousands, except share and per share data)Statement of Operations Data:Revenues:Net patient revenues$7,640$20,956$29,467$33,019$72,357$10,957$25,248Other revenues2831,2751,471904635143215Total revenues7,92322,23130,93833,92372,99211,10025,463Cost of revenues5,66416,97116,96312,70125,5263,7909,519Gross profit2,2595,26013,97521,22247,4667,31015,944Operating expenses:Research and development4,4382,4123,3613,6313,7829901,141General and administrative7,02015,25213,85315,63127,4745,2019,066Sales and marketing3,5277,6956,4566,44815,9683,3205,115Integration, restructuring and other nonrecurring charges——————1,306Total operating expenses14,98525,35923,67025,71047,2249,51116,628Loss from operations(12,726)(20,099)(9,695)(4,488)242(2,201)(684)Other income (expense):Interest income120141971141,622223178Interest expense(74)(989)(1,865)(3,271)(2,222)(1,176)(66)Total other income (expense)46(848)(1,768)(3,157)(600)(953)112Income (loss) before benefit from Income Taxes$(12,680)$(20,947)$(11,463)$(7,645)$(358)$(3,154)$(572)Income Tax benefit——————232Net Loss$(12,680)$(20,947)$(11,463)$(7,645)$(358)$(3,154)$(340)Dividends on and accretion of mandatorily redeemable convertible preferred stock(8,346)(482)(2,597)Net loss applicable to common shares$(12,680)$(20,947)$(11,463)$(7,645)$(8,704)$(3,636)$2,937Net loss per common share(1):Basic and diluted$(5.23)$(7.33)$(4.04)$(2.63)$(2.89)$(1.22)$(0.63)Pro forma$(0.52)Shares used to compute net loss per share(1):Basic and diluted2,423,0722,856,0722,837,7722,908,3603,011,6992,993,0614,694,561Pro forma16,839,493(1)Please
shares used in computation of the per share amounts.35As ofDecember 31,March 31,200820032004200520062007(unaudited)(in thousands)Balance Sheet Data:Cash and cash equivalents$10,106$5,718$2,758$3,909$18,091$61,973Working capital11,8628,6663,648(18,713)29,37571,958Total assets22,15122,80216,45117,170103,040154,766Total debt10,52520,66123,60629,4882,7442,872Total mandatorily redeemable convertible preferred stock————115,302—Total shareholders' equity (deficit)8,000(2,763)(13,660)(19,857)(26,865)135,35136MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONSYou should read the following discussion and analysis of our financial condition and results of our operations in conjunction with our
with the United States Securities and Exchange Commission pursuant to Rule 424(b) (File No. 333-145547) on March 19, 2008.Statements of Operations OverviewRevenuesOur principal source of revenues is patient revenue from cardiac monitoring services.
For our event and Holter monitoring services, we expect gross profit margins to decrease as reimbursement rates decline as currently proposed by CMS.Sales and MarketingSales and marketing expense consists primarily of salaries, benefits and stock-based compensation related to account executives, marketing personnel and
of compliance and increased audit fees resulting from the Sarbanes-Oxley Act. As a percentage of revenues, we expect general and administrative expenses to decline as we grow.Income TaxesWe have net deferred income tax assets totaling approximately $31.2 million at the end of 2007, consisting primarily of federal and state net operating
patient revenues, of which $3.5 million was from the event and Holter monitoring business versus the prior year quarter (full quarter effect in 2008, as the PDSHeart acquisition was consummated
in payments to former PDSHeart stockholders as a result of our initial public offering.Cash Flows from Financing ActivitiesNet cash provided by financing activities during the years ended December 31, 2005, 2006 and 2007 and the three month period ended March 31, 2008
exercise its own discretion in determining salary adjustments and discretionary cash and equity-based awards to recommend to the board of directors for all executive officers.Elements of Executive CompensationThe compensation program for our executive officers consists principally of base salary, long-term compensation in the form of stock options,
the absence of a public trading market for our common stock prior to the closing of our initial public offering, our board of directors and compensation committee determined the fair
realized by us for financial statement reporting purposes in each of 2006 and 2007 in connection with the vesting of shares of common stock that were issued upon exercise of stock options prior to the
realized by us for financial statement reporting purposes in each of 2006 and 2007 in connection with the vesting of outstanding options to purchase shares of our common stock.(3)Mr. Cohen
exercisability of his remaining 41,653 vested stock option shares for a period of one-year following his termination date and (iii) forgiveness of both principal and accrued
$182,800, reflecting six months of Mr. Wood's then base salary, (ii) continued exercisability of 41,653 vested stock option shares for a period of one-year from his
each stock option granted to our named executive officers was equal to the fair market value of our common stock as determined in good faith by our board of directors on the date of the grant.
the per share fair market value of our common stock, as determined in good faith by our board of directors on the grant date.(2)Calculated
of the shares subject to this named executive officer's options were vested as of December 31, 2007.92Option Exercises and Stock VestedThe following table provides information regarding the number of shares of common stock acquired and the value received pursuant to the exercise of stock options
stock bonus awards, and restricted stock awards, which may be granted to our directors, consultants or employees, including officers.Share Reserve.As of March 31, 2008, options to purchase 1,704,804 shares of our common stock issued under the 2003
designate a beneficiary who may exercise the option following the optionholder's death.94Limitations.The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to
receive an initial grant of an option to purchase 15,000 shares of our common stock upon his or her election, subject to adjustment by our board of directors from time to time.
compensation, nominating and corporate governance committee will automatically receive a grant of an option to purchase 7,500 shares of our common stock upon his or her election, subject to adjustment
meeting date, beginning with our 2008 annual meeting, an option to purchase 5,000 shares of our common stock, or the annual grant, subject to adjustment by our board of directors from time to time.
realized by us for financial statement reporting purposes in 2007 in connection with the vesting of outstanding options to purchase shares of our common stock.102(3)Dr. KenKnight
15,000 shares of common stock under our 2003 plan with an exercise price equal to the then fair market value of our common stock on the date of grant and each non-employee director serving
as a chairperson of the compensation or audit committee on July 27, 2007 was granted an additional non-statutory option to purchase 7,500 shares of common stock under our 2003 plan
non-employee directors as described under "—Equity Benefit Plans" above, including an initial grant to purchase up to 15,000 shares of our common stock upon
During the year ended December 31, 2007, the Company issued common stock to non employees for services.
Company's after-tax net income for year ended December 31, 2007 and the period ended March 31, 2008 was $778,508 and $211,000 lower, respectively, as a result of stock-based
The plan provides that the option price shall not be less than the fair market value of the shares on the date of the grant.F-35PDSHEART, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)December 31, 20062.